CareLit Fachartikel

Therapeutic genome editing with engineered nucleases

Haas, S.; Dettmer, V.; Cathomen, T. · Zeitschrift für Orthopädie und Unfallchirurgie · 2017 · Heft 01 · S. 45 bis 52

Dokument
613902
CareLit-ID
Jahr
2017
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Orthopädie und Unfallchirurgie
Autor:innen
Haas, S.; Dettmer, V.; Cathomen, T.
Ausgabe
Heft 01 / 2017
Jahrgang 37
Seiten
45 bis 52
Erschienen: 2017-01-01 00:00:00
ISSN
0720-9355;2567-5761
DOI
10.5482/hamo-16-09-0035

Zusammenfassung

SummaryTargeted genome editing with designer nucleases, such as zinc finger nucleases, TALE nucleases, and CRISPR-Cas nucleases, has heralded a new era in gene therapy. Genetic disorders, which have not been amenable to conventional gene-addition-type gene therapy approaches, such as disorders with dominant inheritance or diseases caused by mutations in tightly regulated genes, can now be treated by precise genome surgery. Moreover, engineered nucleases enable novel genetic interventions to fight infectious diseases or to improve cancer immunotherapies. Here, we review the development of the different classes of…

Schlagworte

Nucleases Genome Editing Therapy Genetic Disorders Diseases Engineered Summarytargeted Designer Finger Crispr-Cas Zeitschrift für Orthopädie und Unfallchirurgie